SMFM特别声明:超越手术刀——宫内胎儿基因治疗与治愈性医学
该声明指出,随着CRISPR-Cas9等基因编辑系统的进步,宫内精准基因组编辑即将实现;镰状细胞病因单基因、不可逆损害和限制生命的并发症成为理想候选。基因治疗已在青少年患者中证明有效,但胎儿免疫系统、母体免疫反应、脱靶效应、胎龄限制及伦理问题等障碍仍需解决,但并非不可逾越。
要点
- 宫内基因编辑技术接近临床,镰状细胞病是优先候选。
- 基因治疗已在青少年患者中显示有效。
- 胎儿免疫、母体免疫、脱靶效应、胎龄和伦理是主要障碍。
核心结论
- 宫内胎儿基因治疗治疗镰状细胞病和其他疾病虽面临障碍,但并非不可逾越,应积极推进。
研究设计与样本
- 学会特别声明,由母胎医学会制定,基于现有文献综述。
主要发现
- 基因编辑系统如CRISPR-Cas9的进步使宫内精准基因组编辑即将实现。
- 镰状细胞病是宫内基因治疗的理想候选,因单基因、不可逆损害和限制生命的并发症。
- 基因治疗已在青少年患者中证明有效。
临床怎么用
- 临床应关注宫内基因治疗的研究进展和伦理问题。
局限性
- 对胎儿免疫系统了解不完整。
- 母体对宫内基因治疗的免疫反应不明确。
- 基因编辑脱靶效应风险。
- 胎龄限制。
- 胎儿遗传干预的伦理问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the recent advances in gene editing with systems such as CRISPR-Cas9, precise genome editing in utero is on the horizon. Sickle cell disease is an excellent candidate for in utero fetal gene therapy, because the disease is monogenic, causes irreversible harm, and has life-limiting morbidity. Gene therapy has recently been proven to be effective in an adolescent patient. Several hurdles still impede the progress for fetal gene therapy in humans, including an incomplete understanding of the fetal immune system, unclear maternal immune responses to in utero gene therapy, risks of off-target effects from gene editing, gestational age constraints, and ethical questions surrounding fetal genetic intervention. However, none of these barriers appears insurmountable, and the journey to in utero gene therapy for sickle cell disease and other conditions should be well underway.
引用
- Shanahan MA, Aagaard KM, McCullough LB, et al. Society for Maternal-Fetal Medicine Special Statement: Beyond the scalpel: in utero fetal gene therapy and curative medicine. Am J Obstet Gynecol. 2021. PMID: 34537158. doi:10.1016/j.ajog.2021.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。